Prospects and challenges of induced pluripotent stem cells as a source of hematopoietic stem cells.
Many life-threatening hematological diseases are now treated by bone marrow transplantations, i.e., infusion of hematopoietic stem cells (HSCs). HSC transplantations are a valid option for the treatment of a variety of metabolic disorders, and even for solid tumors and some refractory severe autoimmune diseases. Unfortunately, the frequency and outcome of HSC transplantations are limited by a shortage of suitable donors. Induced pluripotent stem cells (iPSCs)--somatic cells that have acquired pluripotent stem cell characteristics by the ectopic expression of pluripotency-inducing factors--have been proposed as an alternative source of HSCs. Possible applications include cells of autologous, of autologous and genetically modified, or of allogeneic origin. Here, we provide a perspective on the distinct opportunities of iPSCs and discuss the challenges that lie ahead.
Department of Molecular Cell Biology, Regenerative Medicine Program, Leiden University Medical Center, Leiden, the Netherlands.
Dirk W
DW
van Bekkum
Harald M M
HM
Mikkers
D002454:Cell Differentiation; D006402:Hematologic Diseases / Q000628:therapy; D019337:Hematologic Neoplasms / Q000628:therapy; D006410:Hematopoiesis; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects / Q000379:methods*; D006801:Humans; D057026:Induced Pluripotent Stem Cells / Q000166:cytology* / Q000637:transplantation*; D012449:Safety; D014182:Transplantation, Autologous; D014184:Transplantation, Homologous